Cargando…

Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer

BACKGROUND: A considerable proportion of estrogen receptor (ER)-positive breast cancer recurs despite tamoxifen treatment, which is a serious problem commonly encountered in clinical practice. We tried to find novel prognostic markers in this subtype of breast cancer. METHODS: We performed array com...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Wonshik, Han, Mi-Ryung, Kang, Jason Jongho, Bae, Ji-Yeon, Lee, Ji Hyun, Bae, Young Ju, Lee, Jeong Eon, Shin, Hyuk-Jae, Hwang, Ki-Tae, Hwang, Sung-Eun, Kim, Sung-Won, Noh, Dong-Young
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1459182/
https://www.ncbi.nlm.nih.gov/pubmed/16608533
http://dx.doi.org/10.1186/1471-2407-6-92
_version_ 1782127470672084992
author Han, Wonshik
Han, Mi-Ryung
Kang, Jason Jongho
Bae, Ji-Yeon
Lee, Ji Hyun
Bae, Young Ju
Lee, Jeong Eon
Shin, Hyuk-Jae
Hwang, Ki-Tae
Hwang, Sung-Eun
Kim, Sung-Won
Noh, Dong-Young
author_facet Han, Wonshik
Han, Mi-Ryung
Kang, Jason Jongho
Bae, Ji-Yeon
Lee, Ji Hyun
Bae, Young Ju
Lee, Jeong Eon
Shin, Hyuk-Jae
Hwang, Ki-Tae
Hwang, Sung-Eun
Kim, Sung-Won
Noh, Dong-Young
author_sort Han, Wonshik
collection PubMed
description BACKGROUND: A considerable proportion of estrogen receptor (ER)-positive breast cancer recurs despite tamoxifen treatment, which is a serious problem commonly encountered in clinical practice. We tried to find novel prognostic markers in this subtype of breast cancer. METHODS: We performed array comparative genomic hybridization (CGH) with 1,440 human bacterial artificial chromosome (BAC) clones to assess copy number changes in 28 fresh-frozen ER-positive breast cancer tissues. All of the patients included had received at least 1 year of tamoxifen treatment. Nine patients had distant recurrence within 5 years (Recurrence group) of diagnosis and 19 patients were alive without disease at least 5 years after diagnosis (Non-recurrence group). RESULTS: Potential prognostic variables were comparable between the two groups. In an unsupervised clustering analysis, samples from each group were well separated. The most common regions of gain in all samples were 1q32.1, 17q23.3, 8q24.11, 17q12-q21.1, and 8p11.21, and the most common regions of loss were 6q14.1-q16.3, 11q21-q24.3, and 13q13.2-q14.3, as called by CGH-Explorer software. The average frequency of copy number changes was similar between the two groups. The most significant chromosomal alterations found more often in the Recurrence group using two different statistical methods were loss of 11p15.5-p15.4, 1p36.33, 11q13.1, and 11p11.2 (adjusted p values <0.001). In subgroup analysis according to lymph node status, loss of 11p15 and 1p36 were found more often in Recurrence group with borderline significance within the lymph node positive patients (adjusted p = 0.052). CONCLUSION: Our array CGH analysis with BAC clones could detect various genomic alterations in ER-positive breast cancers, and Recurrence group samples showed a significantly different pattern of DNA copy number changes than did Non-recurrence group samples.
format Text
id pubmed-1459182
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-14591822006-05-11 Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer Han, Wonshik Han, Mi-Ryung Kang, Jason Jongho Bae, Ji-Yeon Lee, Ji Hyun Bae, Young Ju Lee, Jeong Eon Shin, Hyuk-Jae Hwang, Ki-Tae Hwang, Sung-Eun Kim, Sung-Won Noh, Dong-Young BMC Cancer Research Article BACKGROUND: A considerable proportion of estrogen receptor (ER)-positive breast cancer recurs despite tamoxifen treatment, which is a serious problem commonly encountered in clinical practice. We tried to find novel prognostic markers in this subtype of breast cancer. METHODS: We performed array comparative genomic hybridization (CGH) with 1,440 human bacterial artificial chromosome (BAC) clones to assess copy number changes in 28 fresh-frozen ER-positive breast cancer tissues. All of the patients included had received at least 1 year of tamoxifen treatment. Nine patients had distant recurrence within 5 years (Recurrence group) of diagnosis and 19 patients were alive without disease at least 5 years after diagnosis (Non-recurrence group). RESULTS: Potential prognostic variables were comparable between the two groups. In an unsupervised clustering analysis, samples from each group were well separated. The most common regions of gain in all samples were 1q32.1, 17q23.3, 8q24.11, 17q12-q21.1, and 8p11.21, and the most common regions of loss were 6q14.1-q16.3, 11q21-q24.3, and 13q13.2-q14.3, as called by CGH-Explorer software. The average frequency of copy number changes was similar between the two groups. The most significant chromosomal alterations found more often in the Recurrence group using two different statistical methods were loss of 11p15.5-p15.4, 1p36.33, 11q13.1, and 11p11.2 (adjusted p values <0.001). In subgroup analysis according to lymph node status, loss of 11p15 and 1p36 were found more often in Recurrence group with borderline significance within the lymph node positive patients (adjusted p = 0.052). CONCLUSION: Our array CGH analysis with BAC clones could detect various genomic alterations in ER-positive breast cancers, and Recurrence group samples showed a significantly different pattern of DNA copy number changes than did Non-recurrence group samples. BioMed Central 2006-04-12 /pmc/articles/PMC1459182/ /pubmed/16608533 http://dx.doi.org/10.1186/1471-2407-6-92 Text en Copyright © 2006 Han et al; licensee BioMed Central Ltd.
spellingShingle Research Article
Han, Wonshik
Han, Mi-Ryung
Kang, Jason Jongho
Bae, Ji-Yeon
Lee, Ji Hyun
Bae, Young Ju
Lee, Jeong Eon
Shin, Hyuk-Jae
Hwang, Ki-Tae
Hwang, Sung-Eun
Kim, Sung-Won
Noh, Dong-Young
Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer
title Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer
title_full Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer
title_fullStr Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer
title_full_unstemmed Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer
title_short Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer
title_sort genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1459182/
https://www.ncbi.nlm.nih.gov/pubmed/16608533
http://dx.doi.org/10.1186/1471-2407-6-92
work_keys_str_mv AT hanwonshik genomicalterationsidentifiedbyarraycomparativegenomichybridizationasprognosticmarkersintamoxifentreatedestrogenreceptorpositivebreastcancer
AT hanmiryung genomicalterationsidentifiedbyarraycomparativegenomichybridizationasprognosticmarkersintamoxifentreatedestrogenreceptorpositivebreastcancer
AT kangjasonjongho genomicalterationsidentifiedbyarraycomparativegenomichybridizationasprognosticmarkersintamoxifentreatedestrogenreceptorpositivebreastcancer
AT baejiyeon genomicalterationsidentifiedbyarraycomparativegenomichybridizationasprognosticmarkersintamoxifentreatedestrogenreceptorpositivebreastcancer
AT leejihyun genomicalterationsidentifiedbyarraycomparativegenomichybridizationasprognosticmarkersintamoxifentreatedestrogenreceptorpositivebreastcancer
AT baeyoungju genomicalterationsidentifiedbyarraycomparativegenomichybridizationasprognosticmarkersintamoxifentreatedestrogenreceptorpositivebreastcancer
AT leejeongeon genomicalterationsidentifiedbyarraycomparativegenomichybridizationasprognosticmarkersintamoxifentreatedestrogenreceptorpositivebreastcancer
AT shinhyukjae genomicalterationsidentifiedbyarraycomparativegenomichybridizationasprognosticmarkersintamoxifentreatedestrogenreceptorpositivebreastcancer
AT hwangkitae genomicalterationsidentifiedbyarraycomparativegenomichybridizationasprognosticmarkersintamoxifentreatedestrogenreceptorpositivebreastcancer
AT hwangsungeun genomicalterationsidentifiedbyarraycomparativegenomichybridizationasprognosticmarkersintamoxifentreatedestrogenreceptorpositivebreastcancer
AT kimsungwon genomicalterationsidentifiedbyarraycomparativegenomichybridizationasprognosticmarkersintamoxifentreatedestrogenreceptorpositivebreastcancer
AT nohdongyoung genomicalterationsidentifiedbyarraycomparativegenomichybridizationasprognosticmarkersintamoxifentreatedestrogenreceptorpositivebreastcancer